> A randomized placebo controlled trial to assess the safety and efficacy of spironolactone on cardiovascular outcomes among patients with end-stage renal disease.
> The primary objective is to determine if spironolactone reduces cardiac morbidity and mortality for patients treated with chronic dialysis.
Sample Size: Globally 2750 participants & 500 participants from India.
Study Update: In India, 168 patients are into run-in and 98 patients have been randomized.
Updated as of 2nd Sep, 2020